We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02829723
Recruitment Status : Terminated
First Posted : July 12, 2016
Last Update Posted : December 7, 2022
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:

The purpose of this first-in-human (FIH) study of BLZ945 given as a single agent or in combination with PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLZ945, administered orally, as a single agent or in combination with PDR001, administered intravenously (i.v.) in adult patients with advanced solid tumors.

Dose escalation was guided by a Bayesian logistic regression model with overdose control. Once MTD/ RP2D was declared, glioblastoma patients were enrolled in the phase II part to further assess the preliminary anti-tumor activity of BLZ945 as single agent and in combination with PDR001.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: BLZ945 Drug: PDR001 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 198 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors
Actual Study Start Date : October 21, 2016
Actual Primary Completion Date : December 1, 2022
Actual Study Completion Date : December 1, 2022

Arm Intervention/treatment
Experimental: BLZ945 single agent Drug: BLZ945
Experimental: BLZ945 + PDR001 Drug: BLZ945
Drug: PDR001

Primary Outcome Measures :
  1. Incidence of Dose limiting toxicities (Phase I) [ Time Frame: 5 years ]
    To identify the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D)

  2. Incidence of Adverse Events (Phase I) [ Time Frame: 5 years ]
    To identify the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D)

  3. Incidence of Serious Adverse Events (Phase I) [ Time Frame: 5 years ]
    To identify the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D)

  4. Dose interruptions (Phase I) [ Time Frame: 5 years ]
    To identify the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D)

  5. Dose reductions (Phase I) [ Time Frame: 5 years ]
    To identify the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D)

  6. Dose intensity (Phase I) [ Time Frame: 5 years ]
    To identify the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D)

  7. Progression-free survival probability (PFSP) at 6 months (Phase II) [ Time Frame: 6 months ]
    Percentage of participants with Progression Free Survival (PFS) at 6 months per RANO criteria

Secondary Outcome Measures :
  1. Progression Free Survival (PFS) (Phase I) [ Time Frame: 5 years ]
    Evaluation is based on RECISTv1.1 or irRC or RANO or iRANO

  2. Best Overall Response (BOR) (Phase I) [ Time Frame: 5 years ]
    Evaluation is based on RECISTv1.1 or irRC or RANO or iRANO

  3. Disease Control Rate (DCR) (Phase I) [ Time Frame: 5 years ]
    Evaluation is based on RECISTv1.1 or RANO

  4. PFS (Phase II) [ Time Frame: 5 years ]
    Evaluation is based on iRANO

  5. BOR (Phase II) [ Time Frame: 5 years ]
    Evaluation is based on RANO or iRANO

  6. Duration Of Response (DOR) (Phase II) [ Time Frame: 5 years ]
    Evaluation is based on RANO or iRANO

  7. DCR (Phase II) [ Time Frame: 5 years ]
    Evaluation is based on RANO or iRANO

  8. Overall Survival (OS) (Phase II) [ Time Frame: 6 years ]
    every 12 weeks until end of study

  9. Incidence of AEs (Phase II) [ Time Frame: 5 years ]
  10. Incidence of SAEs (Phase II) [ Time Frame: 5 years ]
    Assessment to be completed at least every 28 days

  11. Pharmacokinetics (PK) Area Under the Curve (AUC) (BLZ945 single agent) [ Time Frame: 5 years ]
  12. PK AUC (BLZ945 + PDR001) [ Time Frame: 5 years ]
  13. PK Time of maximum concentration observed (Tmax) (BLZ945 single agent) [ Time Frame: 5 years ]
  14. PK Tmax (BLZ945 + PDR001) [ Time Frame: 5 years ]
  15. PK peak serum concentration (Cmax) (BLZ945 + PDR001) [ Time Frame: 5 years ]
  16. PK Cmax (BLZ945 single agent) [ Time Frame: 5 years ]
  17. Concentration of anti-PDR001 antibodies (BLZ945 + PDR001) [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Phase I: Patients with advanced/metastatic solid tumors, with measurable or unmeasurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
  2. Phase I: Patients with a site of disease amenable to biopsy, and willing to undergo a new tumor biopsy at screening, and during treatment.
  3. Phase II: Patients with advanced/metastatic/recurrent isocitrate dehydrogenase (IDH) wild-type glioblastoma, with at least one measurable lesion as determined by RANO

Other protocol defined inclusion criteria may apply

Exclusion Criteria:

  1. History of severe hypersensitivity reactions to monoclonal antibodies.
  2. Impaired cardiac function or clinically significant cardiac disease.
  3. Active autoimmune disease or a documented history of autoimmune disease.
  4. Systemic steroid therapy or any immunosuppressive therapy
  5. Use of any vaccines against infectious diseases within 4 weeks of initiation of study treatment.
  6. Patient receiving treatment with medications that either strong inducers or inhibitors of CYP2C8 or CYP3A4/5, or patients receiving medication that prohibits proton pump inhibitors and that cannot be discontinued at least 1 week prior to start of treatment and for the duration of the study.

Other protocol defined exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02829723

Layout table for location information
United States, Massachusetts
Dana Farber Cancer Institute Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, Tennessee
Sarah Cannon Research Institute Sarah Cannon Research
Nashville, Tennessee, United States, 37203
United States, Texas
UT M.D Anderson Cancer Center
Houston, Texas, United States, 77030
Cancer Therapy and Research Center UT Health Science Center
San Antonio, Texas, United States, 78229
Novartis Investigative Site
Tel Aviv, Israel, 6423906
Novartis Investigative Site
Rozzano, MI, Italy, 20089
Novartis Investigative Site
Nagoya, Aichi, Japan, 466 8560
Novartis Investigative Site
Koto ku, Tokyo, Japan, 135 8550
Novartis Investigative Site
Singapore, Singapore, 169610
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site
Hospitalet de LLobregat, Catalunya, Spain, 08907
Novartis Investigative Site
Madrid, Spain, 28041
Novartis Investigative Site
Zurich, Switzerland, 8091
Novartis Investigative Site
Taipei, Taiwan, 10002
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02829723    
Other Study ID Numbers: CBLZ945X2101
2015-005806-12 ( EudraCT Number )
First Posted: July 12, 2016    Key Record Dates
Last Update Posted: December 7, 2022
Last Verified: December 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Phase I/II
Additional relevant MeSH terms:
Layout table for MeSH terms
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents